NASDAQ:IFRX InflaRx (IFRX) Stock Price, News & Analysis $0.86 +0.04 (+4.70%) As of 02:23 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About InflaRx Stock (NASDAQ:IFRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get InflaRx alerts:Sign Up Key Stats Today's Range$0.82▼$0.8950-Day Range$0.73▼$1.8552-Week Range$0.71▼$2.82Volume347,727 shsAverage Volume293,462 shsMarket Capitalization$57.63 millionP/E RatioN/ADividend YieldN/APrice Target$6.60Consensus RatingBuy Company Overview InflaRx NV is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutic antibodies targeting components of the innate immune system. The company’s lead program is vilobelimab (IFX-1), a monoclonal antibody that selectively inhibits the complement factor C5a, a potent driver of inflammation. InflaRx is advancing vilobelimab in multiple indications, including hidradenitis suppurativa, paroxysmal nocturnal hemoglobinuria and other rare and severe inflammatory diseases, with both ongoing and planned clinical trials. Founded in 2007 and headquartered in Jena, Germany, InflaRx maintains operational offices in the United States to support its North American development and regulatory activities. The company has established strategic collaborations for manufacturing and clinical research in Europe and North America, ensuring access to state-of-the-art facilities and patient populations. InflaRx completed its initial public offering on the NASDAQ stock exchange in 2019 to accelerate its pipeline advancement and expand global clinical programs. Under the leadership of Chief Executive Officer Jan Schmidt, InflaRx is led by a management team with extensive experience in immunology, drug development and regulatory affairs. The company’s board and scientific advisory group include industry veterans from biotechnology and pharmaceutical backgrounds who guide strategy and clinical program design. InflaRx remains committed to translating its complement-modulating platform into novel therapies that address unmet needs in inflammatory and autoimmune diseases worldwide.AI Generated. May Contain Errors. Read More InflaRx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreIFRX MarketRank™: InflaRx scored higher than 54% of companies evaluated by MarketBeat, and ranked 476th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingInflaRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageInflaRx has only been the subject of 3 research reports in the past 90 days.Read more about InflaRx's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for InflaRx are expected to decrease in the coming year, from ($1.04) to ($1.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of InflaRx is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of InflaRx is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInflaRx has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about InflaRx's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.10% of the float of InflaRx has been sold short.Short Interest Ratio / Days to CoverInflaRx has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in InflaRx has recently decreased by 7.09%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInflaRx does not currently pay a dividend.Dividend GrowthInflaRx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.10% of the float of InflaRx has been sold short.Short Interest Ratio / Days to CoverInflaRx has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in InflaRx has recently decreased by 7.09%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for InflaRx this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for IFRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added InflaRx to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, InflaRx insiders have not sold or bought any company stock.Percentage Held by Insiders16.30% of the stock of InflaRx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.39% of the stock of InflaRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about InflaRx's insider trading history. Receive IFRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InflaRx and its competitors with MarketBeat's FREE daily newsletter. Email Address IFRX Stock News HeadlinesInflaRx N.V. (IFRX) Latest Stock News & Headlines - Yahoo FinanceJuly 4, 2025 | finance.yahoo.comInflaRx Appoints KPMG as New Auditor Following Shareholder ApprovalJune 27, 2025 | tipranks.comA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.July 8 at 2:00 AM | American Alternative (Ad)InflaRx stock rating cut, price target slashed to $2 by Raymond JamesMay 30, 2025 | investing.comInflaRx Earnings Estimates, EPS & Revenue | NASDAQ:IFRX | BenzingaMay 30, 2025 | benzinga.comInflaRx’s Strategic Shift to INF904: A Promising Focus Amidst Early-Stage UncertaintyMay 29, 2025 | tipranks.comInflaRx N.V.: InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma GangrenosumMay 28, 2025 | finanznachrichten.deInflaRx plunges on plans to halt studies into lead asset in rare skin disorderMay 28, 2025 | msn.comSee More Headlines IFRX Stock Analysis - Frequently Asked Questions How have IFRX shares performed this year? InflaRx's stock was trading at $2.47 on January 1st, 2025. Since then, IFRX stock has decreased by 65.2% and is now trading at $0.8585. How were InflaRx's earnings last quarter? InflaRx N.V. (NASDAQ:IFRX) announced its earnings results on Wednesday, May, 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.04. The firm had revenue of $0.03 million for the quarter, compared to analysts' expectations of $0.03 million. When did InflaRx IPO? InflaRx (IFRX) raised $100 million in an IPO on Wednesday, November 8th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO. How do I buy shares of InflaRx? Shares of IFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of InflaRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that InflaRx investors own include G1 Therapeutics (GTHX), Xeris Biopharma (XERS), Bristol Myers Squibb (BMY), Enterprise Products Partners (EPD), Exelixis (EXEL), Tesla (TSLA) and Alibaba Group (BABA). Company Calendar Last Earnings5/07/2025Today7/08/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IFRX CIK1708688 Webwww.inflarx.de Phone493641508180Fax49-36-4150-8181Employees60Year FoundedN/APrice Target and Rating Average Stock Price Target$6.60 High Stock Price Target$10.00 Low Stock Price Target$2.00 Potential Upside/Downside+686.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$49.85 million Net MarginsN/A Pretax Margin-33,646.85% Return on Equity-64.17% Return on Assets-53.39% Debt Debt-to-Equity RatioN/A Current Ratio5.28 Quick Ratio4.86 Sales & Book Value Annual Sales$180 thousand Price / Sales312.90 Cash FlowN/A Price / Cash FlowN/A Book Value$1.13 per share Price / Book0.74Miscellaneous Outstanding Shares67,130,000Free Float56,190,000Market Cap$56.32 million OptionableOptionable Beta1.29 10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:IFRX) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Cold War “Accident” Could Unleash New $100 Trillion AI BoomObscure Metal More Valuable than Gold and Bitcoin… COMBINED? This strange "AI Metal" holds the key to the $...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InflaRx N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share InflaRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.